Trial Profile

A phase 3 study study of Celecoxib/ciprofloxacin

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 11 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Nov 2025 According to a NeuroSense Therapeutics media release, the U.S. Food and Drug Administration (FDA) has completed the review of the Investigational New Drug (IND) amendment application and authorized the Company to initiate the pivotal Phase 3 clinical trial for the evaluation of its lead drug candidate, PrimeC, for the treatment of amyotrophic lateral sclerosis (ALS).
03 Nov 2025 According to a NeuroSense Therapeutics media release, company will host an investor update meeting on December 8, 2025 at 8:30 a.m. Eastern Time. and Company plans to provide status update on study initiation.
24 Apr 2025 According to a NeuroSense Therapeutics media release, the company releases letter to shareholders outlining Phase 3 timeline for PrimeC in ALS

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com